Dennis Slamon
Oncólogo americano
>
Dennis Joseph Slamon, es un oncólogo estadounidense y jefe de la división de Hematología-Oncología de UCLA. Es mejor conocido por su trabajo en la identificación del oncogén HER2/neu que se amplifica en entre el 25% y el 33% de los pacientes con... Wikipedia (Inglés)
Nacimiento: 6 de agosto de 1948 (edad 75 años), New Castle, Pensilvania
Educación: Universidad de Chicago y Washington & Jefferson College
Dennis J. Slamon, MD, PhD serves as director of Clinical/Translational Research, and as director of the Revlon/UCLA Women's Cancer Research Program at JCCC.
Más preguntas
Who discovered Herceptin?
How many lives has Herceptin saved?
Is Herceptin worth it?
Where was Herceptin developed?
Dennis J Slamon ... Dr. Dennis J. Slamon holds the Bowyer Professor of Medical Oncology. ... Publications listed below are automatically derived from MEDLINE/PubMed ...
Slamon, professor and chief of hematology/oncology at the David Geffen School of Medicine at UCLA, to the groundbreaking development of the breast cancer drug ...
25 nov 2023 · Dr. Slamon serves as Director of Clinical/Translational Research and Director of the Revlon/UCLA Women's Cancer Research Program at Jonsson ...
Dr. Dennis Slamon '70 is best known for the research he conducted that led to the development of Herceptin, a breast cancer drug that targets a specific ...
Acclaimed for having brought about a revolution in breast cancer diagnosis and treatment, Dr. Slamon and colleagues began looking at alterations in genes ...
Dennis J. Slamon, M.D., Ph.D., joined our Board in March 2014. Dr. Slamon has served as director of Clinical/ Translational Research at UCLA's Jonsson ...
First person profile: Dennis J. Slamon, MD, PhD: Dr. Slamon's pioneering work helped lead to the breakthrough breast cancer drug trastuzumab, which has saved ...
2 jun 2023 · Dennis Slamon, MD, PhD, lead investigator on the NATALEE trial of ribociclib plus hormonal therapy in hormone receptor–positive, HER2-negative ...